Adaptin Bio, Inc. (APTN) Fair Value 2026

APTN · Biological Products, (No Diagnostic Substances) ·

By CirclFi Research Team · Data from SEC EDGAR, FRED & GDELT

Quality Score

4.0 /10

32 fundamental signals · 0 models active

Value Trap Risk

SAFE (10/100)

Quick Summary — As of 2026-08-27, Adaptin Bio, Inc. (APTN) trades at $6.27. QOC: 4.0/10. Value Trap Risk: 10/100 (SAFE). 0/13 models active.

Key Facts

Ticker
APTN
Price
$6.27
Quality Score
4.0/10
Value Trap Risk
10/100
Models Active
0/13
Last Updated
Strength: 0 independent models provide multi-angle coverage
Risk: Below-average Quality Score of 4.0/10 signals weak fundamentals

What Fair Value Does Each Model Give APTN?

0 Intrinsic Value Models vs. Current Price ($6.27)

Core Models (Unlocked)
Model Fair Value Upside

All Models Active

All 0 models are displayed above.

What Is Adaptin Bio, Inc. (APTN) Worth in 2026?

According to the CirclFi Deep Alpha Valuation Engine, Adaptin Bio, Inc. currently lacks sufficient data across our 13-model framework. As more financial data is processed from SEC filings, our models will generate intrinsic value estimates.

What Do the Models Say About APTN?

0 of 13 models are currently active for APTN. See which stocks rank higher →

How Does APTN Rank in Biological Products, (No Diagnostic Substances)?

Among 2 Biological Products, (No Diagnostic Substances) stocks, APTN ranks #1 by Quality of Company score. CirclFi's QOC score of 4.0/10 evaluates 32 fundamental signals. A score of 4.0 signals below-average fundamentals.

Adaptin Bio, Inc. operates in a competitive landscape where fundamental quality metrics are key differentiators for long-term value creation.

Is APTN a Value Trap?

CirclFi's Value Trap algorithm assigns APTN a score of 10/100 (SAFE). This indicates minimal risk. Fundamentals are healthy. The score cross-references apparent undervaluation against fundamental deterioration signals. Browse lowest value-trap stocks →

Multi-Model Methodology

0 of 13 models are active for Adaptin Bio, Inc.. Limited activation may indicate insufficient history. Each model applies a fundamentally different valuation philosophy. See the complete methodology →

According to the CirclFi Quality of Company (QOC) framework, which evaluates 32 signals including margin stability, revenue growth trajectory, leverage, and free cash flow generation, Adaptin Bio, Inc. is rated at 4.0/10. This moderate-tier score shows mixed signals across our quality framework with notable weaknesses.

CirclFi runs 13 independent models for each stock. Browse all stocks with 13-model coverage →

Data Sources & Confidence

Every APTN valuation is built from SEC EDGAR XBRL filings — 700+ standardized financial tags. Macroeconomic context from FRED calibrates discount rates, while GDELT news sentiment feeds into our Sentiment SOTP model. All pipelines run daily. Read the complete data methodology →

CirclFi's output is a research starting point, not a buy/sell signal. All data updates daily. Read the full methodology →

This analysis is produced by the CirclFi Valuation Engine using quantitative models applied to SEC EDGAR filings, public market feeds, and FRED macroeconomic indicators. It is not financial advice.

Read the full investment analysis: Should You Buy Adaptin Bio, Inc. Stock in 2026? →

Bull case, bear case, risk factors & peer comparison — updated daily

Which Similar Biological Products, (No Diagnostic Substances) Stocks Should You Also Analyze?

1 related Biological Products, (No Diagnostic Substances) stocks with 13-model coverage

CVMCEL-SCI CorporationQOC 3.9

Read investment analysis: CVM

Which Other Stocks Have a Similar Quality Score to APTN?

7 companies across all industries closest to APTN’s Quality of Company score of 4.0/10.

DOGPDogecoin Cash, Inc.QOC 4.0SBEVSplash Beverage Group, Inc.QOC 4.0ADIGADI Global Distribution IncQOC 4.0DRMADermata Therapeutics, Inc.QOC 4.0VBIOValion Bio, Inc.QOC 4.0NDRAENDRA Life Sciences Inc.QOC 4.0NVDANVIDIA CorporationQOC 10.0

Read investment analysis: DOGP · SBEV · ADIG · DRMA · VBIO · NDRA · NVDA

What Else Do Investors Ask About Adaptin Bio, Inc.’s Valuation?

What is Adaptin Bio, Inc.'s intrinsic value in 2026?

CirclFi does not yet have enough active models to publish a median fair value for Adaptin Bio, Inc. (APTN). The Quality of Company score is 4.0/10 across 32 fundamental signals. All models use SEC EDGAR filings updated daily. See our methodology page for how each model works.

Is APTN overvalued or undervalued right now?

At $6.27, 0 of 0 active models suggest APTN may be undervalued, while 0 indicate potential overvaluation. The assessment depends on which methodology best fits Adaptin Bio, Inc.'s business model in Biological Products, (No Diagnostic Substances).

What does a Quality of Company score of 4.0 mean for APTN?

Adaptin Bio, Inc.'s QOC of 4.0/10 reflects 32 fundamental signals: profitability margins, revenue growth consistency, balance sheet leverage, free cash flow generation, and capital allocation efficiency. Scores below 5 flag potential fundamental weaknesses requiring careful analysis.

How many valuation models does CirclFi run on APTN?

CirclFi analyzes APTN with 13 institutional-grade models daily: Bayesian DCF (Monte Carlo + jump-diffusion), EPV (Greenwald zero-growth), EROIC Spread (McKinsey reinvestment), First Chicago (3-scenario), Markov DDM (regime-switching), ML-RIV (machine learning residual income), Dynamic NAV (asset-based), PWERM (option-theoretic), Regime Cross-Sectional (relative), Sentiment SOTP (hybrid), CUCE Ensemble (meta-model), FTNN Topology (neural network), and RCMH-DCF (conditional regime). Currently 0 of 13 are active for this stock. Read the full methodology →

Is APTN a value trap in 2026?

Adaptin Bio, Inc.'s Value Trap score is 10/100 (SAFE). This low score indicates the current valuation is not artificially depressed by fundamental deterioration, suggesting genuine opportunity rather than a trap. Browse stocks by value-trap risk →

Cite this analysis — “CirclFi assigns Adaptin Bio, Inc. (APTN) a Quality of Company score of 4.0/10 across 32 fundamental signals as of 2026-08-27.” Source: circlfi.com/stock/APTN/ · Methodology
Primary sources for this APTN valuation
  • Financial statements: Adaptin Bio, Inc. 10-K and 10-Q filings on SEC EDGAR (CIK 0001938571) — 700+ standardized XBRL tags, published by the U.S. Securities and Exchange Commission.
  • Discount-rate inputs: FRED, Federal Reserve Bank of St. Louis — risk-free rates, VIX, yield curve, inflation.
  • News sentiment: The GDELT Project — global media tone, input to the Sentiment SOTP model.
  • Model definitions: CirclFi methodology — the published specification for all 13 models, including the academic sources each one implements.

Market data for APTN as of ; valuations recomputed .